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The results of cytostatic therapy in metastatic melanoma are very disappointing. In phase II studies 
with high-dose cisplatin regimens, a remarkably high response rate was observed. In a phase I study 
with a short course of weekly cisplatin, combined with oral etoposide, we were able to reach, in most 
patients, a cisplatin dose intensity of 60 mg/m2/week. We performed a phase II study with this schedule 
in metastatic malignant melanoma. 15 consecutive patients were entered in the study. Treatment 
consisted of cisplatin 70 mg/m2 on days 1, 8, 15 and days 29,36,43 combined with oral etoposide 50 mg 
daily, days 1-15 and days 29-43. Patients with a response or stable disease continued treatment with 
oral etoposide 50 mglm’ daily, days 1-21 every 4 weeks. All patients were evaluable for response and 
toxicity. The majority of the patients received six cycles of cisplatin with the planned cisplatin dose 
intensity of 60 mg/m2/week. A partial response was observed in 2 patients (13%; 95% confidence interval 
(CI) 2-44%) of, respectively, 22 and 12 weeks; stable disease was observed in 6 patients. Toxicity 
consisted mainly of alopecia and bone marrow suppression. 4 patients had tinnitus, one patient had 
neurotoxicity grade 1. The regimen studied has only limited activity in metastatic melanoma in spite 
of the high-dose intensity of cisplatin reached with this schedule.Copyright 0 1996 Elsevier Science Ltd 
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INTRODUCTION 
DESPITE THE introduction of new cytotoxic drugs and immun- 
otherapy with IL-2 and interferons, the grim prognosis for 
patients with metastatic malignant melanoma has not 
improved over the last decade. Since the early 197Os, dacarba- 
zine (DTIC) has been considered the drug of first choice, 
although response rates in various schedules never exceed 
30% and responses are in general of short duration [l]. In 
combination regimens of DTIC with cisplatin, BCNU and/or 
vindesine, occasionally response rates of >40% have been 
reported [2]. Some patients will occasionally reach a durable 
complete response [3, 41. Cisplatin as a single agent adminis- 
tered at a conventional dose and schedule yields a response 
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rate of lo-15% [5, 61. Glover and associates performed a 
phase II study with high-dose cisplatin in combination with 
WR-2721 every 3-4 weeks (71. In this study, 19 out of 36 
patients responded (53%). Out of 4 patients treated with 
cisplatin at a dose 5100 mgim’ none responded, while 5 out 
of 6 patients treated with an initial cisplatin dose of 150 mgim’ 
responded. This suggests that a higher cisplatin dose intensity 
might be of benefit. In a phase I study with a short course of 
weekly cisplatin, combined with oral etoposide, we were able 
to administer cisplatin at a dose intensity of 60 mglm’iweek in 
most patients [8]. We performed a series of phase II studies 
with this regimen in solid tumours which, based on the 
positive results of Glover and associates, also included meta- 
static melanoma. A response rate of at least 40% was con- 
sidered of interest as lower response rates can be achieved 
with less intensive treatment. 
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PATIENTS AND METHODS Table 1. Patient characteristics 
Patients were required to have histological proof of malig- 
nant melanoma with distant metastases, a WHO performance 
status of 2 or better, white blood cell count B3.0 X 10911, 
platelet count > 100 X 1 09/1, creatinine clearance >60 mlimin 
and a serum bilirubin ~25 p,mol/l. All patients had a full 
medical history and physical examination before start of treat- 
ment, an ECG, chest X-ray and CT-scan of the chest and 
abdomen with and without i.v. contrast and, if appropriate, 
clinical measurement of pathological lymph nodes or skin 
metastases. CT-scan of the brain and bone scintigraphy were 
only performed on indication. All patients had a neurological 
examination including estimation of the vibration perception 
threshold before the start, after completion of treatment and 
3 months thereafter. All patients gave oral informed consent. 
No. of patients entered 
Male:female 
Median age, years (range) 
Median I’S (range) 
Previous treatment 
15 
9:6 
44 (34-55) 
1 (O-l) 
Immunotherapy (IL-2 + OL IFN) 
Chemotherapy 
None 
Dominant site of metastases 
Visceral 13 
Lymph nodes 2 
During treatment, patients had a weekly physical examin- 
ation, assessment of toxicity, full blood counts and estimation 
of serum electrolytes, calcium, magnesium, creatinine and 
liver function tests as well as a creatinine clearance. 
apy consisting of systemic IL-2 plus a-interferon on which 
treatment one patient had a partial response. 
Response to treatment was assessed 2 weeks after the last 
cisplatin administration and every 8 weeks thereafter. The 
standard WHO criteria were used for evaluation of response 
and toxicity [9]. 
Treatment schedule 
Cisplatin was administered at a dose of 70 mgim’ on days 
1, 8, 15 and days 29, 36,43; oral etoposide was administered 
at a dose of 50 mg daily, days 1-l 5, and days 29-43. During 
cisplatin administration, patients were hospitalised for 24 h. 
The treatment regimen consisted of prehydration with 
1000 ml dextrose-saline, 20 mmol KC1 and 1 gram MgSO, in 
4 h; cisplatin powder was dissolved in 250 ml 3% NaCl and 
administered over 3 h followed by posthydration with 2 litres 
of dextrose-saline, 40 mmol KC1 and 2 grams MgS04 in 8 h. 
As anti-emetic treatment, 8 mg ondansetron was given as a 
slow i.v. bolus directly before starting the cisplatin adminis- 
tration and was repeated, if necessary, after 12 h. In case of 
delayed nausea and vomiting, metoclopramide 20 mg three 
times daily was given orally or per suppository. 
All 15 patients were evaluable for response and toxicity. 
The side-effects, reported as worst toxicity observed during 
the whole treatment period, are shown in Table 2. All patients 
developed anaemia, 6 patients required packed cell trans- 
fusions for a total of 31 units. Leucocytopenia grade 3 was 
observed in only 4 patients, thrombocytopenia grade 3 in one 
and grade 4 in one patient. None of the patients required a 
platelet transfusion and there were no eposides of neutro- 
penic fever. 
Non-haematological toxicities observed were: alopecia in all 
patients, neurotoxicity grade 1 was observed in only one 
patient. Nephrotoxicity was not observed in this study. 4 
patients had ototoxicity grade 2 (tinnitus) according to the 
NCI-Common Toxicity Criteria. The median weight loss 
during therapy was 4 kg (range l-1 0 kg). 
Dose reductions were not allowed. If at the day of planned 
cisplatin administration WBC were <2.5 X lo911 and/or plate- 
lets were <75 X log/l, treatment was postponed until recovery 
above these values with a maximum delay of 2 weeks. In case 
of a delay of >2 weeks or in case of neuro- or nephrotoxicity 
grade 2, patients were taken off study. Patients responding to 
treatment, or with stable disease at first response evaluation, 
continued treatment with oral etoposide at a dose of 50 mg/m’ 
daily, days 1-21, every 28 days for a maximum of four cycles. 
Etoposide was administered as 50 mg gelatin capsules and the 
dosage was adjusted such that the administered dose deviated 
<5% from the total planned dose of etoposide. Etoposide 
cycles were postponed in case of WBC c2.5 X 109/1 and/or 
platelets <75 X lo911 until recovery above these values. Dur- 
ing treatment with oral etoposide, full blood counts were 
made every 2 weeks and serum electrolytes, liver and renal 
function tests were carried out every 4 weeks. 
In total, 80 cycles of cisplatin were administered, median 
six per patient (range 3-6). 9 patients completed the treatment 
without any delay and reached the planned cisplatin dose 
intensity of 60 mg/m2/week. In 5 patients, a delay of 1 week 
and in one patient a delay of 2 weeks was necessary because 
of slow bone marrow recovery. 
2 patients had a partial response: the woman previously 
responding to DTIC had a partial response of skin and a renal 
metastasis lasting 22 weeks; the second patient, a man with 
skin and lymph node metastases, had a partial response of 12 
weeks duration. The overall response rate is 13% (95% CI 2- 
44%). 6 patients had stable disease with a median duration of 
26 weeks (range 12-50 weeks). 7 patients had progressive dis- 
ease. 
Table 2. Worst toxicity per patient 
RESULTS 
15 consecutive patients who met the eligibility criteria were 
entered into the study. The patient characteristics are given in 
Table 1. One patient was pretreated with DTIC for skin 
metastases on which treatment she had a short lasting com- 
plete response. 9 patients were pretreated with immunother- 
WHO grade 0 1 2 3 4 
Haemoglobin 06 8 10 
Leucocytes 32640 
Platelets 11 2 0 1 1 
Nausea/vomiting 02 4 9 0 
Neurotoxicity 14 1 0 0 0 
Ototoxicity 11 0 4 0 0 
Nephrotoxicity 15 0 0 0 0 
9 
1 
5 
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8 patients continued oral etoposide after response evalu- 
ation for a median of two cycles per patient (range 14 cycles). 
Reasons not to complete the four planned etoposide cycles 
were progressive disease in 3 patients and refusal in one 
patient. Only one patient with stable disease after the ‘induc- 
tion’ phase had a decrease in size of the metastases during oral 
etoposide but did not meet the criteria for partial response. In 
all other patients, the response status did not improve during 
the treatment with oral etoposide. After entrance of 15 pati- 
ents, the study was closed according to protocol in view ,of the 
low response rate observed. 
DISCUSSION 
The treatment of patients with metastatic melanoma 
remains unrewarding. Only a few treatment schedules with 
minor activity are available. The role of cisplatin in the treat- 
ment of these patients is still a matter of debate. We previously 
reported a response rate of 40% with conventional doses of 
cisplatin in combination with ifosfamide [lo]. Glover and 
colleagues reported a high response rate of 53% with high 
dose cisplatin in combination with the cytoprotector WR- 
2721 [7]. Only patients treated with cisplatin at a dose 
> 100 mg/m* responded. A different high-dose schedule of 
cisplatin 100 mg/m2 days 1 and 8 in combination with WR- 
272 1 was explored by Buzaid and colleagues [ 1 l] but they did 
not observe any response in 9 patients. In both studies, 
the projected cisplatin dose intensity was 50 mg/m2/week. 
Another high-dose cisplatin schedule was published by 
Murren and associates [ 121. Their original schedule consisted 
of cisplatin 100 mg/m” days 1 and 8 combined with DTIC 
300 mg/m’ days 1 and 2 and day 8 and 9, but it had to be 
modified to cisplatin 50 mgim’ plus DTIC 350 mgim’ days 
l-3 every 4 weeks mainly because of renal toxicity. The latter 
regimen was better tolerated and 7 out of 14 patients on this 
regimen responded to treatment. This positive result could, 
however, not be confirmed by others using the same regimen: 
Steffens and associates observed a response rate of only 17% 
while Buzaid and associates, applying the same regimen in 
combination with tamoxifen, observed a response rate of only 
13% [ 13, 141. In these regimens, the projected cisplatin dose 
intensity was 37.5 mg/m*/week. In our study, with a projected 
cisplatin dose intensity of 60 mg/m*/week, which was reached 
in most patients, we observed a response in only 2 out of 15 
patients. These data taken together suggest that the overall 
dose intensity of the course might be less important than a 
high cisplatin dose per administration. The experience with 
single agent etoposide in malignant melanoma is very limited 
and disappointing [ 15, 161. The combination of cisplatin with 
etoposide has been tested in the subcapsular renal assay on 
human metastatic melanoma. In these studies, 15% of the 
implants were sensitive to the combination of cisplati 
etoposide which corresponds to our clinical observation [ 171. 
In our study, continuous oral etoposide was administered for 
reasons of clinical synergy of both drugs in other solid tumours 
and the schedule was used in a broad phase II programme. 
Since we did not observe further response improvements 
during continuation with oral etoposide after the ‘induction’ 
phase with cisplatin, we feel that there are no arguments left 
to explore etoposide further in the treatment of melanoma. 
We conclude that the presently studied regimen has only 
limited activity in melanoma and cannot be recommended in 
this disease. 
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